Applied Therapeutics, Inc. shares rise 1.56% intraday after Elicera Therapeutics AB continues Phase I/IIa CARMA clinical study.

Applied Therapeutics, Inc. rose 1.56% in intraday trading, with Elicera Therapeutics AB (publ) announcing that the Data Safety and Monitoring Board (DSMB) has completed its second assessment of the ongoing Phase I/IIa CARMA clinical study with the CAR T-cell therapy, ELC-301, for the treatment of B-cell lymphoma. The DSMB recommended the continuation of the study as planned.